News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

M. Sieber

Articles by M. Sieber

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany

ByH. Tesch,M. Sieber,J. U. Rüffer,J. Franklin,R. Herrmann,F. Boissevain,A. Franke,M. Pfreundschuh,D. Hossfeld,E. Dühmke,J. Wolf,A. Engert,U. Paulus,V. Diehl

March 1st 1999

BACKGROUND: Extended-field radiotherapy is effective in patients with early-stage Hodgkin’s disease, and more than

Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease

ByV. Diehl,J. Franklin,M. Sieber,D. Hasenclever,U. Paulus,H. Tesch,M. Pfreundschuh,U. Rüffer,R. Hermann,C. Longin,M. Hänel,G. Wulf,W. Aulitzky,A. Georgii,E. Dühmke,M. Loeffler

March 1st 1999

This report aims to assess the effect of increased drug dose on the efficacy and toxicity of the BEACOPP regimen with

Latest Updated Articles

2 Cycles of ABVD Plus Radiotherapy Is More Effective Than Radiotherapy Alone in Early Stage HD-Interim Ahan Radiotherapy Alone in Early Stage HD-Interim Analysis of the HD7 Trial of the GHSG Clinic of Internal Medicine I University of Cologne/Germany
Published: March 1st 1999 | Updated:
Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease
Published: March 1st 1999 | Updated:

Trending on CancerNetwork

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer

Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs

Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC

© 2025 MJH Life Sciences^®

All rights reserved.